Does Medicare Advantage Cover Testosterone Enanthate?

Testosterone enanthate is a long-acting injectable testosterone ester approved by the FDA for replacement therapy in men with confirmed testosterone deficiency. It is not a brand name; the drug has been sold as a generic under this chemical name for decades and is distinct from testosterone cypionate, testosterone undecanoate (Aveed), and topical testosterone gels, which are separate formulations with their own approval histories and coverage rules.

Medicare Advantage (MA) plans that include Part D drug benefits generally do cover testosterone enanthate when it is prescribed for FDA-labeled hypogonadism and the diagnosis is documented the way the plan's utilization management policy requires. Coverage is not automatic and it is not uniform: each MA organization sets its own formulary tier, prior authorization criteria, and step therapy rules within the annual framework CMS establishes, so two plans in the same city can treat the same prescription differently. This is established from CMS's general program structure for Part C and Part D appeals and from the drug's FDA labeling for hypogonadism. What is not established, and what this page cannot verify without your specific plan's current formulary, is the exact copay dollar amount you will pay. That number changes by plan year, region, and pharmacy network, and should be confirmed directly on Medicare.gov's Plan Finder rather than assumed from any published average.

What is established, what is plausible, and what is not established

Established: Testosterone enanthate has an FDA-approved indication for testosterone replacement in men with diagnosed deficiency. The Endocrine Society's 2018 guideline recommends confirming the diagnosis with at least two morning total testosterone measurements using a reliable assay before starting therapy (Bhasin et al., 2018). Medicare Part D, including the Part D portion of Medicare Advantage, statutorily excludes coverage for drugs used primarily for weight loss.

Plausible but not verifiable from public CMS pricing data: Most industry commentary describes testosterone enanthate as landing on a low generic tier (commonly described as Tier 2 or Tier 3) on most MA-PD formularies, since it has been genericized for decades and its manufacturing cost is low relative to branded alternatives like Aveed. This is a reasonable inference from how CMS-regulated formularies tier generic versus branded drugs generally, but it is not a claim this article can attach to a specific dollar figure without checking your plan's current formulary document.

Not established: Any single "typical copay" figure, wholesale cost, or cash-pay average cited in this space should be treated as unverified unless it comes from your plan's own summary of benefits or a current pricing tool. Prices and tier placement change yearly and by region, and no primary source in this review supports a fixed number.

How Medicare Advantage decides whether to pay

CMS does not issue a single national coverage determination for testosterone replacement therapy. Instead, each Medicare Advantage organization files its own formulary with CMS and applies its own utilization management rules on top of the federal minimum requirements. That means the real answer to "will my plan cover this" lives in your plan's formulary and prior authorization policy document, not in a general article. Checking the specific plan's current formulary on Medicare.gov before filling a prescription is the most reliable single step a reader can take, because plan design changes at least annually.

Prior authorization: what plans commonly ask for

Almost every Medicare Advantage plan requires prior authorization before covering testosterone enanthate, and incomplete submissions are the most common cause of delay or denial. Criteria commonly track the Endocrine Society's diagnostic framework:

• A documented diagnosis of male hypogonadism (commonly coded ICD-10 E29.1)
• Two morning total testosterone levels, drawn before symptoms and lab-draw timing consistent with the Endocrine Society's recommendation, showing values in the deficient range
• Documented symptoms consistent with low testosterone (fatigue, low libido, erectile dysfunction, loss of muscle mass)
• Consideration of reversible causes such as opioid use or untreated obstructive sleep apnea

Individual carriers may layer additional requirements, such as baseline PSA and hematocrit, or labs to distinguish primary from secondary hypogonadism. Because these requirements vary by carrier and change over time, verify the current checklist against your specific plan's published prior authorization policy rather than assuming any single list is universal.

A prior authorization submission is stronger when it includes dated lab values, the working diagnosis, symptom documentation, and a short clinical note connecting the two. Prescribers who submit this up front generally avoid the additional-information request cycle that otherwise delays approval.

Does a plan require trying a topical gel first?

Some Medicare Advantage plans apply step therapy, requiring a documented trial of topical testosterone before authorizing the injectable. Where this applies, plans typically want to see either an inadequate testosterone response on topical therapy, a skin reaction, or a documented reason topical therapy is inappropriate. The FDA's labeling for topical testosterone gel carries a boxed warning about secondary exposure to children and pregnant partners through skin contact, and this warning is a legitimate clinical basis for a prescriber to request a step therapy exception rather than trial a topical first, particularly in a household with young children.

Not every plan imposes step therapy, and a formulary exception request with a specific clinical rationale can bypass it where a plan does. There is no general number this article can quote for how often exceptions are granted.

What Medicare Advantage will not pay for

Medicare Part D plans cannot cover testosterone enanthate when the primary purpose is weight loss. This is a statutory Part D exclusion, not a plan choice. The 2023 SELECT trial showed a reduction in major cardiovascular events with semaglutide 2.4 mg in adults with obesity or overweight and established cardiovascular disease, which is why that specific drug and dose carries a narrow path to coverage under an added cardiovascular indication (Lincoff et al., SELECT, 2023). Testosterone enanthate has no comparable FDA-approved cardiovascular or weight-management indication, so a claim submitted under an obesity diagnosis code will be denied regardless of documentation quality.

It is worth being precise about what the TRAVERSE trial actually showed, because it is often misquoted in this context. TRAVERSE enrolled men with hypogonadism and elevated cardiovascular risk and found that testosterone replacement therapy did not increase the rate of major adverse cardiac events compared with placebo over the trial period, as reported in the cardiovascular safety literature on testosterone replacement therapy. That is a cardiovascular safety finding, a demonstration of non-inferiority, not evidence of a cardiovascular benefit and not the basis for a weight-loss or cardio-protective indication. Coverage decisions correctly treat these as different categories of evidence.

Coverage is also not extended to testosterone prescribed for age-related decline in the absence of a confirmed deficiency. The Endocrine Society guideline recommends against diagnosing or treating testosterone deficiency without both consistent symptoms and unequivocally low morning testosterone values, and MA prior authorization criteria generally reflect that standard (Bhasin et al., 2018).

The trial evidence plans lean on

When medical directors evaluate testosterone coverage policy, the Testosterone Trials (TTrials) are a frequently cited evidence base. This coordinated set of placebo-controlled trials enrolled 790 men aged 65 and older with low serum testosterone and symptoms of hypogonadism. The Sexual Function Trial, published in the New England Journal of Medicine in 2016, reported that testosterone treatment improved sexual desire, erectile function, and sexual activity compared with placebo over 12 months. The Physical Function Trial found a modest improvement in walking distance, and the Vitality Trial did not reach statistical significance on its primary fatigue endpoint, though some secondary fatigue measures trended favorably (Snyder et al., 2016).

The trial population matters for coverage logic: these were older men with confirmed low testosterone and corresponding symptoms, not young men with normal testosterone seeking performance enhancement. Prior authorization criteria that mirror this population are consistent with the trial evidence; prescribing patterns that fall well outside it are less likely to be approved and, separately, are less supported by the evidence itself.

Appealing a denial

Medicare Advantage plans are required to provide a structured appeal process with federally defined timelines. If a prior authorization for testosterone enanthate is denied, the first step is a plan-level redetermination, generally filed within 60 days of the denial notice, with documentation addressing the specific reason cited. Standard redeterminations are subject to defined decision timelines under CMS rules, with faster turnaround for requests marked as clinically urgent.

If the plan upholds its denial, the case proceeds to an independent review entity under contract with CMS, currently MAXIMUS Federal Services, which reviews the clinical record independent of the plan's own medical directors. Additional appeal levels exist beyond that, including an Administrative Law Judge hearing above a dollar threshold that CMS updates periodically, followed by the Medicare Appeals Council and federal court. Because the ALJ dollar threshold changes from year to year, confirm the current figure on the CMS appeals page rather than relying on a number printed in this article.

In practice, the most effective single action is a timely, complete redetermination request that directly answers whatever the denial letter says was missing, whether that is a lab value, a diagnosis code, or step therapy documentation.

Testosterone enanthate versus other covered formulations

Medicare Advantage formularies typically list several testosterone options, and cost or tier placement can differ meaningfully between them even though the clinical effect is similar.

Testosterone enanthate and testosterone cypionate are both generic injectables with comparable pharmacokinetics (cypionate has a somewhat longer half-life), and most plans place them on the same tier, treating them as interchangeable for coverage purposes. Generic topical gels are also commonly placed on a low generic tier, though gel manufacturing costs run higher than injectable esters. Branded topical products and testosterone undecanoate (Aveed), which is administered in a clinical setting roughly every ten weeks, are typically placed on higher, non-preferred or specialty tiers with correspondingly higher cost-sharing, and some plans require documented failure of self-administered options before covering Aveed. For a reader focused purely on minimizing predictable out-of-pocket cost within Medicare Advantage, a generic injectable ester (enanthate or cypionate) is generally the lower-tier option, though the exact tier and copay must be confirmed on the specific plan's formulary.

A decision framework for navigating coverage

Use this sequence before assuming a denial is final or a cost estimate is accurate. It reflects how MA prior authorization and appeals actually work, not a universal price list.

The throughline: a denial tied to missing documentation is winnable through the standard appeal path, while a denial tied to an off-label purpose (weight loss, age-related decline without confirmed deficiency) reflects a categorical Part D rule that resubmission will not overturn.

Practical tips for a first-attempt approval

Confirm the diagnosis with two documented morning testosterone levels drawn under the conditions your plan or the Endocrine Society guideline specifies, with dates recorded. Include baseline labs your plan is known to request. Use the diagnosis code that matches true hypogonadism, not a symptom code or an obesity code. If step therapy applies, document any prior topical trial with dates and the reason for discontinuation. A short clinical note connecting symptoms, labs, and the treatment rationale, submitted with the initial request rather than after a denial, is the most consistent way to shorten the approval timeline.

When to involve your prescriber urgently

Testosterone replacement is not an emergency medication, and a coverage delay is an administrative problem, not a medical one, in most cases. Contact your prescriber promptly, rather than waiting for an appeal to resolve, if you experience symptoms that could indicate a medication problem rather than a coverage problem, such as unexplained swelling, shortness of breath, chest pain, or signs of an allergic reaction. Those symptoms warrant urgent evaluation regardless of insurance status.